Summary

Restrictions on sharing mice engineered with a technology patented by DuPont, which permits precise deletion of genes in specific cells, have drawn protests from prominent researchers. Some organizations, including the Howard Hughes Medical Institute, have accepted the conditions, but others, including the National Institutes of Health, have declined. NIH director Harold Varmus is trying to persuade DuPont to relax its rules.